NYSE$BLCO
Bausch + Lomb Corp · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Bausch + Lomb reported Q3 2025, revenue of $1.18B, net income of $95M, diluted EPS of $0.38.
For Q3 2025, Bausch + Lomb reported revenue of $1.18B, net income of $95M, diluted EPS was $0.38. Management discusses segment trends, capital allocation, and macro risks in the quarterly filing.
- Revenue $1.18B.
- Net income $95M.
- Diluted EPS $0.38.
- Bausch + Lomb MD&A highlights operating priorities and liquidity.
- Segment and geographic mix shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Bausch + Lomb · Revenue · Quarterly
$1.28B
Revenue by segment
Bausch + Lomb · $1.01B total across 3 segments · Q3 2023
- Vision Care$648M+8.4%64.3%
- Surgical$185M+7.6%18.4%
- Pharmaceuticals$174M+1.2%17.3%
Forward guidance
Medical technology outlook ties to procedure volumes, approvals, and reimbursement.
Tailwinds
- New product adoption and clinical data.
- Geographic expansion.
- Manufacturing scale.
Headwinds
- Reimbursement changes.
- Competitive entrants.
- Hospital capital budgets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
-1.0%
Avg return
Earnings day
-1.8%
Avg return
5 days after
-1.0%
Avg return
30 days after
43%
9 / 21 earnings
Positive
+18.7%
Q4 2023
Best reaction
-15.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | +2.9% | -1.0% | |
| Q4 2025 | +0.2% | +1.5% | -11.3% | |
| Q3 2025 | +2.1% | +0.3% | +6.5% | |
| Q1 2025 | -15.7% | -17.1% | -16.4% | |
| Q4 2024 | -0.3% | -3.3% | -4.8% | |
| Q3 2024 | -2.3% | -4.3% | -4.5% | |
| Q2 2024 | -0.1% | -8.7% | -2.6% | |
| Q1 2024 | -4.7% | -0.7% | +5.5% | |
| Q4 2023 | +18.7% | +15.7% | +10.8% | |
| Q3 2023 | +4.6% | +2.9% | -4.3% | |
| Q2 2023 | -2.5% | -3.4% | -7.2% | |
| Q1 2023 | +0.1% | +4.6% | +4.4% | |
| Q4 2020 | +0.4% | -3.7% | -14.1% | |
| Q4 2022 | +0.4% | -3.7% | -14.1% | |
| Q3 2022 | -4.9% | +5.6% | +7.9% | |
| Q3 2021 | -4.9% | +5.6% | +7.9% | |
| Q2 2022 | +4.7% | +6.3% | +1.2% | |
| Q2 2021 | +4.7% | +6.3% | +1.2% | |
| Q1 2022 | -6.8% | -14.6% | +5.0% | |
| Q4 2021 | -6.8% | -14.6% | +5.0% | |
| Q1 2021 | -6.8% | -14.6% | +5.0% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro